Pharmadrug Inc. (LMLLF)
- Previous Close
0.0070 - Open
0.0070 - Bid 0.0060 x --
- Ask 0.0074 x --
- Day's Range
0.0070 - 0.0070 - 52 Week Range
0.0041 - 0.0400 - Volume
7,858 - Avg. Volume
40,691 - Market Cap (intraday)
771,954 - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0100 - Earnings Date May 28, 2025 - Jun 1, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Pharmadrug Inc. operates as a specialty pharmaceutical company. It focuses on the research, development, and commercialization of controlled-substances and natural medicines, such as psychedelics, cannabis, and naturally derived approved drugs. The company also engages in the researching and reformulating of established natural medicines; development of synthetic formulations of existing drugs for potential commercialization and distribution; development of cepharanthine, a drug for the treatment of infectious disease and rare cancers; and research and development activities in the psychedelics space for the treatment of non-neuropsychiatric conditions. It has a license agreement with Southwest Research Institute. The company was formerly known as Aura Health Inc. and changed its name to Pharmadrug Inc. in October 2019. Pharmadrug Inc. is based in Toronto, Canada.
www.pharmadrug.ca--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: LMLLF
View MorePerformance Overview: LMLLF
Trailing total returns as of 5/16/2025, which may include dividends or other distributions. Benchmark is S&P/TSX Composite index (^GSPTSE) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: LMLLF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: LMLLF
View MoreValuation Measures
Market Cap
771.95k
Enterprise Value
1.68M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-41.44%
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-793.27k
Diluted EPS (ttm)
-0.0100
Balance Sheet and Cash Flow
Total Cash (mrq)
75.04k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-500.38k